Stock Events

Stock Events

Bioline Rx 

$2.64
67
-$0.05-1.83% 10:49 Today

Statistics

Day High
2.7
Day Low
2.67
52W High
4.56
52W Low
2.15
Volume
431
Avg. Volume
-
Mkt Cap
11.75M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0
-0
-0
0
Expected EPS
-0.000642
Actual EPS
N/A

Financials

-99.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.18MRevenue
-1.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BLRX. It's not an investment recommendation.
Coca-Cola
9
KO
Realty Income
7
O
Amazon
7
AMZN
Abbvie
7
ABBV

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences operates in similar therapeutic areas as Bioline Rx, including oncology and antiviral drugs, making them direct competitors in drug development and market share.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments in oncology/hematology, which overlaps with Bioline Rx's research and development efforts.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare diseases with a strong pipeline in genetic diseases, competing with Bioline Rx's approach to novel, targeted treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious medical conditions, closely competing with Bioline Rx in the biopharmaceutical space.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals concentrates on creating new possibilities in medicine to cure diseases and improve people's lives, competing in the same innovative drug market as Bioline Rx.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation specializes in oncology products, directly competing with Bioline Rx in developing treatments for cancer.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals, with its focus on RNAi therapeutics, competes in the innovative treatment space, potentially overlapping with Bioline Rx's target diseases and technologies.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in various therapeutic areas, including those targeted by Bioline Rx, making it a competitor in terms of market presence and therapeutic focus.

About

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Show more...
CEO
Philip A. Serlin
Employees
24
Country
Israel
ISIN
US09071M3043
WKN
000A41038

Listings

F
DE
YP2.F
MU
DE
YP2A.MU
STU
DE
YP2.STU
MU
DE
YP2.MU

0 Comments

Share your thoughts

FAQ

What is Bioline Rx stock price today?▼
The current price of BLRX is $2.64 USD — it has decreased by -1.83% in the past 24 hours. Watch Bioline Rx stock price performance more closely on the chart.
What is Bioline Rx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Bioline Rx stocks are traded under the ticker BLRX.
Is Bioline Rx stock price growing?▼
BLRX stock has risen by +3.46% compared to the previous week, the month change is a -2.54% fall, over the last year Bioline Rx has showed a -24.23% decrease.
What is Bioline Rx market cap?▼
Today Bioline Rx has the market capitalization of 11.75M
When is the next Bioline Rx earnings date?▼
Bioline Rx is going to release the next earnings report on November 18, 2026.
What were Bioline Rx earnings last quarter?▼
BLRX earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bioline Rx revenue for the last year?▼
Bioline Rx revenue for the last year amounts to 1.18M USD.
What is Bioline Rx net income for the last year?▼
BLRX net income for the last year is -1.18M USD.
How many employees does Bioline Rx have?▼
As of September 04, 2026, the company has 24 employees.
In which sector is Bioline Rx located?▼
Bioline Rx operates in the Health & Wellness sector.
When did Bioline Rx complete a stock split?▼
The last stock split for Bioline Rx was on January 30, 2025 with a ratio of 1:40.
Where is Bioline Rx headquartered?▼
Bioline Rx is headquartered in Hevel Modi'in, Israel.